Tax laws and regulations are constantly changing, and it can be difficult to keep up with it all. In this blog, CSSI experts share their insights around the most relevant issues and developments impacting your tax situation.
Few industries invest as heavily in research and development as pharmaceuticals. The path from early discovery to an approved therapy is long, expensive, and filled with scientific uncertainty, and that investment is precisely what the federal R&D tax credit under IRC Section 41 was built to reward. Yet despite being one of the most credit-eligible […]
Read More
BioScience companies exist to solve some of the world’s most complex problems: developing new therapeutics, advancing diagnostic tools, engineering biological systems, and pushing the boundaries of what science can achieve. What many of these companies don’t realize is that the same work driving their scientific mission may also be generating significant federal and state tax […]
Read More
The federal R&D tax credit, formally known as the Credit for Increasing Research Activities under IRC Section 41, is one of the most powerful incentives available to U.S. businesses. And for food and beverage companies, the opportunity is frequently overlooked, and significantly underutilized. What Qualifies as R&D in Food & Beverage? The R&D tax credit […]
Read More
What Is the Section 174 Amortization Fix? The Section 174 amortization fix refers to proposed or enacted legislative changes to reverse a controversial tax policy change that took effect in 2022, requiring businesses to amortize, rather than immediately deduct, their research and experimental (R&E) expenditures over five years (15 years for foreign research). Prior to […]
Read MoreHave a question or need assistance? One of our team members will be in touch within the next business day.
